Eli Lilly stock weekly forecast: Remains firm near recent highs with technical support at $1,402

Eli Lilly stock weekly forecast: Remains firm near recent highs with technical support at $1,402
Eli lilly slips 1.99% this week

Shares of Eli Lilly and Company (LLY) are trading near $1,416 after slipping almost 2% this week, as buyers managed to keep the stock near recent highs. The moves come amid continued deal-making and positive regulatory momentum, setting up a week shaped by fresh corporate catalysts and sustained interest in growth from new treatments.

LLY price prediction
24H -0.16%
$1,388.8
48H -0.67%
$1,381.58
7D -0.35%
$1,386.05
1M 11.09%
$1,545.25
3M 33.84%
$1,861.72
6M 18.32%
$1,645.77
12M 42.74%
$1,985.43
Current price: $1,390.96 -23.9900 1.70%
Real-time Data 12:21
Daily range 1385.21 Arrow from to Icon 1413.40
Weekly range 1402.36 Arrow from to Icon 1469.75
Loading...

Highlights

  • Shares of Eli Lilly fell 1.99% over the past week to $1,416, remaining well above key long-term moving averages.
  • Technical structure is bullish with trend strength confirmed, but momentum signals are mixed and Stochastic RSI indicates short-term rebound potential.
  • The stock is expected to consolidate in the $1,385 to $1,446 range in the next five trading days, with $1,402 and $1,469 as closest support and resistance.

Oncology deals and FDA approval drive positive sentiment during the week

Eli Lilly announced a definitive agreement to acquire Calytrix Bio, a biotechnology company focused on rare blood cancers, in a deal valued up to $1.5 billion, as reported by MarketScreener. The company also entered a $5.9 billion partnership with Stipple Bio to advance targeted cancer therapies, according to Benzinga and Fierce Biotech. In addition, the U.S. FDA approved Eli Lilly's RETEVMO (selpercatinib) on November 16, 2026, further expanding its oncology portfolio.

Eli Lilly and Company asset chart
Eli Lilly and Company price dynamics. Source: TradingView.

Technical momentum signals diverge as support levels limit further downside

On the daily chart, the structure remains robust but with some divergence in momentum signals. MACD reads 63.91 with a strong buy direction, while ADX at 36.96 also supports ongoing trend strength, but Stochastic RSI sits in its oversold zone, flagging potential for a short-term rebound amid this 4.81% weekly volatility. The nearest support is $1,402 and resistance stands at $1,469, with the Ichimoku Kijun at $1,314 acting as additional support. This signals a firm trend with a sustained move lower, suggesting downside risks may be contained unless support fails.

Consolidation expected with bullish bias unless support breaks next week

For the next five trading days, the expected range is $1,385 to $1,446, with a 76% probability of an increase and a 24% probability of a decrease. Base case: the stock consolidates inside this range. A close above $1,469 opens up bullish momentum, while a drop below $1,402 would expose further downside.

Viktoras Karapetjanc, Traders Union expert, sees Eli Lilly stock holding near $1,416 this week as buyers remain engaged despite a minor 2% dip. He highlights significant corporate actions, including the $1.5 billion Calytrix Bio acquisition and a $5.9 billion partnership with Stipple Bio, along with ongoing regulatory gains as strong drivers of long-term growth sentiment. Daily technicals confirm robust trend strength, with upside potential supported by a strong MACD and solid ADX, while Stochastic RSI in oversold territory signals room for a short-term rebound. For the coming week, consolidation is likely between $1,385 and $1,446, but any close above $1,469 could quickly revive bullish momentum. "Major partnerships and expanding approvals fortify my optimistic view on Eli Lilly — any advance above $1,469 is a clear opportunity to capture further gains in the days ahead."

Previously it was reported that Eli Lilly agreed to acquire Calytrix Bio in a bid to expand its presence in rare blood cancer treatments. The current trading setup suggests the $1,402 support level is critical to watch over the coming sessions, as a decisive break could signal further downside beyond the established consolidation range.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.